(2) Lack of evaluation of genetic and serum biomarker testing in these trials, as NSCLC patients harboring EGFR mutations and increased levels of serum HDL-cholesterol were associated with better PFS and OS in the metformin combination group [74, 96]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.